[ad_1]
Progyny, Inc. (NASDAQ: PGNY) Director Norman Payson sold 8,330 shares of the company in a trade on Wednesday, January 5. The stock was sold for an average price of $ 46.99, for a total value of $ 391,426.70. The sale was disclosed in a document filed with the SEC, which is available at this link.
Norman Payson has also recently done the following job (s):
- On Wednesday December 22, Norman Payson sold 8,330 Progyny shares. The stock was sold for an average price of $ 50.62, for a total value of $ 421,664.60.
- On Wednesday December 15, Norman Payson sold 8,330 Progyny shares. The stock was sold for an average price of $ 47.60, for a total value of $ 396,508.00.
- On Wednesday, December 8, Norman Payson sold 8,330 Progyny shares. The stock was sold for an average price of $ 50.65, for a total value of $ 421,914.50.
- On Wednesday December 1, Norman Payson sold 8,330 Progyny shares. The stock was sold for an average price of $ 50.13, for a total value of $ 417,582.90.
- On Tuesday, November 23, Norman Payson sold 8,130 Progyny shares. The shares were sold for an average price of $ 54.26, for a total value of $ 441,133.80.
- On Wednesday November 17, Norman Payson sold 8,330 Progyny shares. The shares were sold for an average price of $ 63.36, for a total value of $ 527,788.80.
- On Wednesday November 10, Norman Payson sold 8,330 Progyny shares. The shares were sold for an average price of $ 63.18, for a total value of $ 526,289.40.
- On Wednesday November 3, Norman Payson sold 8,330 Progyny shares. The shares were sold for an average price of $ 61.40, for a total value of $ 511,462.00.
- On Wednesday October 27, Norman Payson sold 8,330 Progyny shares. The shares were sold for an average price of $ 60.69, for a total value of $ 505,547.70.
- On Wednesday October 20, Norman Payson sold 8,330 Progyny shares. The shares were sold for an average price of $ 58.74, for a total value of $ 489,304.20.
Whether you are looking to learn the basics of futures or are a seasoned veterinarian looking to hone your trading skills, our technical analysis guide has everything you need to be successful in today’s futures markets. hui!
NASDAQ: PGNY traded at $ 2.27 during Friday trading hours, reaching $ 43.78. 920,390 shares of the company were traded for an average volume of 874,336. The company has a market cap of $ 3.96 billion, a P / E ratio of 48.64 and a beta of 1.72. Progyny, Inc. has a twelve month low of $ 38.61 and a twelve month high of $ 68.32. The stock’s fifty-day moving average price is $ 53.97 and its two hundred-day moving average price is $ 55.68.
Progyny (NASDAQ: PGNY) last released its quarterly results on Thursday, November 4. The company reported earnings per share of $ 0.17 for the quarter, beating the consensus estimate of $ 0.06 by $ 0.11. Progyny recorded a return on equity of 29.67% and a net margin of 18.96%. The company posted revenue of $ 122.30 million for the quarter, compared to $ 125.52 million according to analysts’ estimates. During the same period of the previous year, the company achieved earnings per share of $ 0.05. Progyny’s quarterly revenue increased 23.7% year-on-year. As a group, research analysts predict that Progyny, Inc. will post 0.54 EPS for the current year.
Several equity research analysts recently commented on the company. JPMorgan Chase & Co. increased its price target on Progyny from $ 65.00 to $ 79.00 and rated the company “overweight” in a report released on Friday, October 22. Citigroup downgraded Progyny from a “buy†rating to a “neutral†rating and increased its target price for the company from $ 60.00 to $ 64.00 in a report released on Monday, November 22. Barclays raised its price target on Progyny from $ 72.00 to $ 80.00 and rated the company “overweight” in a report released on Tuesday, September 28. Zacks Investment Research downgraded Progyny from a “buy†rating to a “keep†rating in a report released on Wednesday, November 10. Finally, Berenberg Bank took over the coverage of Progyny in a report published on Thursday, September 30. They set a “buy” rating and a target price of $ 81.00 for the company. Three analysts rated the stock with a conservation rating and six issued a buy rating for the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $ 68.25.
A number of hedge funds have recently changed their holdings in the company. BlackRock Inc. strengthened its position in Progyny by 41.2% in the 3rd quarter. BlackRock Inc. now owns 7,787,503 shares of the company valued at $ 436,101,000 after purchasing an additional 2,272,422 shares during the last quarter. Macquarie Group Ltd. strengthened its position in Progyny by 15.0% in the 3rd quarter. Macquarie Group Ltd. now owns 6,920,250 shares of the company valued at $ 387,534,000 after purchasing an additional 900,432 shares during the last quarter. Vanguard Group Inc. increased its position in Progyny by 17.6% in the second quarter. Vanguard Group Inc. now owns 5,197,239 shares of the company valued at $ 306,637,000 after purchasing an additional 777,703 shares during the last quarter. Clearbridge Investments LLC strengthened its position in Progyny by 16.1% in the 2nd quarter. Clearbridge Investments LLC now owns 2,929,152 shares of the company valued at $ 172,820,000 after purchasing an additional 406,870 shares during the last quarter. Finally, Voya Investment Management LLC strengthened its position in Progyny by 40.0% in the 3rd quarter. Voya Investment Management LLC now owns 1,798,663 shares of the company valued at $ 100,725,000 after purchasing an additional 513,460 shares during the last quarter. 85.61% of the shares are currently held by institutional investors.
Company Profile Progyny
Progyny, Inc, an employee benefit management company, specializes in fertility and family building benefit solutions for employers in the United States. Its fertility benefits solution includes a differentiated benefit plan design, concierge-style personalized member support services and a selective network of fertility specialists.
Further reading: what is a stock of electric vehicles?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Progyny now?
Before you consider Progyny, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the top five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and Progyny was not on the list.
While Progyny currently has a “Buy†rating among analysts, top-rated analysts believe these five stocks are better bids.
See the 5 actions here
[ad_2]
Comments are closed.